Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Hemay005 in Healthy Subjects
NCT04837235Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mufemilast in psoriasis (3 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Number of adverse events (AEs), related AEs and serious AEs (SAEs). Started Apr 2021; status: completed.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04837235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837235.